

PRESS RELEASE

Hansa Biopharma: Increase of the number of shares and votes

Lund, Sweden, December 30, 2022. Hansa Biopharma AB "Hansa" or the "Company", (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the Company's registered share capital and number of outstanding shares and votes have increased during the month of December 2022 as a result of the directed share issue announced on December 13, 2022.

Through the directed share issue, 7,848,111 new ordinary shares were issued and the share capital increased by SEK 7,848,111. As of today, the total number of registered shares of the Company amounts to 55,034,241, whereof 52,443,962 are ordinary shares and 2,590,279 are class C shares. As of today, the number of votes in the Company amounts to 52,702,989.9, and the registered share capital amounts to SEK 55,034,241.

This information is information that Hansa Biopharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on December 30, 2022, at 8:00 CET.

--ENDS--

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving, and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy, and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.